Thomas Malcolm

Chief Executive Officer @ Porcine Therapeutics

About

Executive officer who is highly dedicated and motivated to develop novel biotechnologies to improve the lives of patients. Over 20 years of experience in the life sciences. A natural acuity for linking science, intellectual property/licensing and commercial business into fortified and successful endeavors. Critical thinking and integrity-driven professional with a deep understanding of shareholder value and loyalty.

Country

United States

City

Jersey City

Industry

Research

Skill

Vaccines, Vector, Technical Operations, Laboratory Safety, Investigational New Drug Application (IND), Interpersonal Skills, Gene Delivery, Medical Diagnostics, Metabolomics, Molecular Biology, Assay Development, Cell Biology, Biochemistry, Mammalian Cell Culture, Bacterial Cell Culture, Column Chromatography, Affinity Chromatography, Ion Chromatography, DNA sequencing, DNA methylation

Experience

Chief Executive Officer

Porcine Therapeutics

2025-1 - Present · 1 yr 9 mos

Denver, Colorado, United States

Chief Operating Officer (Founder)

Porcine Therapeutics

2019-7 - 2025-1 · 5 yrs 7 mos

Denver, Colorado, United States

www.kermodebio.com At Kermode Biotechnologies, we are dedicated to pioneering solutions in animal health, with a focus on combating the African Swine Fever Virus (ASFV). Founded on the principles of innovation and scientific excellence, our team is developing novel vaccines that leverages unique protein antigen subunits to elicit strong immune responses in swine. With roots in both New York and Shenzhen, we bridge the gap between cutting-edge research and practical applications. Our mission is to safeguard global swine populations, enhance food security, and support farmers worldwide. Through relentless pursuit of groundbreaking research, Kermode Biotechnologies stands at the forefront of animal disease prevention, transforming challenges into opportunities for a healthier future.

Biotech Advisor

Hippocrates Opportunity Fund

2024-9 - Present · 2 yrs 1 mo

New York, New York, United States

HOF is a venture fund dedicated to nurturing pre-seed, seed and Series A investments in the Biotechnology sector.

Chief Scientific and Innovations Officer (Founder)

Caravan Biologix

2021-9 - Present · 5 yrs 1 mo

Princeton, New Jersey, United States

Chief Executive Officer (Founder)

Caravan Biologix

2020-5 - 2021-9 · 1 yr 5 mos

Princeton, New Jersey, United States

www.caravanbio.com At Caravan Biologix, our focus is on leveraging the Mini-CAR technology to address critical human diseases. Our therapeutic platform provides a versatile foundation for developing nearly unlimited differentials of Mini-CAR that can be tailored to treat different human diseases, demonstrating our dedication to advancing healthcare on multiple fronts.

Scientific Advisor

Ferghana Partners

2019-6 - Present · 7 yrs 4 mos

New York, New York, United States

www.ferghanapartners.com Ferghana is a leading, “content strong” investment banking firm servicing the Life Sciences sector; specializing in the healthcare and specialty chemicals sectors. The company consistently meets and exceeds its clients’ high expectations.

US Board Member

Gylden Pharma

2023-3 - 2025-9 · 2 yrs 7 mos

Doylestown, Pennsylvania, United States

www.emergexvaccines.com Emergex, a clinical-stage, privately held biotechnology company headquartered in Oxfordshire, Abingdon, UK, with R&D facilities in Milton Park, UK, an operating subsidiary in Doylestown, Pennsylvania, and GMP manufacturing facility in Fremont, CA, USA. Emergex is pioneering the development a range of 100% synthetic CD8+ T cell-priming immune set-point candidates designed to harness the body’s natural cellular immune response to destroy pathogen-infected cells and to provide broad and robust immune protection for some of the world’s most urgent infectious diseases.